Wednesday, 6 February 2019

Eli Lilly cuts 2019 forecast on trial failure, Loxo deal

Eli Lilly cut its 2019 profit forecast on Wednesday, hit by a recent trial failure of conditionally approved cancer treatment Lartruvo and costs related to its pending acquisition of Loxo Oncology.

from Earnings https://cnb.cx/2HWOrJj
via IFTTT
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)